Angelean Hendrix, Ph.D.

Angelean Hendrix, PhD, is an executive leader and mathematician specializing in quantitative modeling and clinical pharmacology strategy. With expertise spanning pharmacometrics, quantitative systems pharmacology (QSP), and AI/ML, she develops mechanistic models that drive model-informed drug development (MIDD), translational toxicology, and efficacy prediction. Dr. Hendrix has led pharmacometric strategies for multiple rare disease programs, guiding initiatives from discovery through post-marketing and supporting regulatory, clinical, and translational decisions across the drug development continuum. 

At the intersection of science and leadership, Dr. Hendrix has directed cross-functional teams in product development, marketing, and business development for AI/ML-based pharmacometrics platforms. She has advanced R&D roadmaps, built strategic partnerships, and represented her organization at global conferences, strengthening both innovation and industry collaboration. Passionate about translating complex science into meaningful therapeutic impact, she continues to mentor emerging scientists and foster a culture of creativity, rigor, and excellence in model-informed drug development.